Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome

View post:
Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Related Posts